Safety and Efficacy of the 2.25-mm Sirolimus-Eluting Bx Velocity Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: the SIRIUS 2.25 Trial

Smaller reference vessel diameter is a recognized determinant of in-stent restenosis. The SIRIUS 2.25 trial was a prospective, nonrandomized study including 100 patients (mean age 63.4 years; 64% men, 40% with diabetes mellitus) assessing the safety and efficacy of the 2.25-mm sirolimus-eluting Bx V...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2006-12, Vol.98 (11), p.1455-1460
Main Authors: Moses, Jeffrey W., Nikolsky, Eugenia, Mehran, Roxana, Cambier, Patrick A., Bachinsky, William B., Leya, Fred, Kuntz, Richard E., Popma, Jeffrey J., Schleckser, Patricia, Wang, Hong, Cohen, Sidney A., Leon, Martin B.
Format: Article
Language:English
Subjects:
Angioplasty, Balloon, Coronary
Biological and medical sciences
Cardiology. Vascular system
Cardiovascular disease
Clinical trials
Coronary Restenosis
Coronary Stenosis - therapy
Diabetes
Diabetes Complications - therapy
Female
Humans
Male
Medical sciences
Middle Aged
Multivariate analysis
Patients
Prospective Studies
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Sirolimus - administration & dosage
Stents
Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Smaller reference vessel diameter is a recognized determinant of in-stent restenosis. The SIRIUS 2.25 trial was a prospective, nonrandomized study including 100 patients (mean age 63.4 years; 64% men, 40% with diabetes mellitus) assessing the safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in patients with de novo native coronary lesions. Using propensity score matching for gender, diabetes mellitus, left anterior descending artery target vessel, lesion length, and reference vessel diameter, the outcomes were compared with historical control groups (angioplasty and Palmaz-Schatz stent arms from the STRESS/BENESTENT I/II trials and the Bx Velocity bare metal stent arm from the RAVEL and SIRIUS trials having a reference vessel diameter
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2006.06.047